摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(2-cyano-3-(3-methyl-4-oxo-3,4-dihydroquinazolin-6-ylamino)phenyl)propane-1-sulfonamide | 1396310-74-9

中文名称
——
中文别名
——
英文名称
N-(2-cyano-3-(3-methyl-4-oxo-3,4-dihydroquinazolin-6-ylamino)phenyl)propane-1-sulfonamide
英文别名
N-{2-Cyano-3-[(3-Methyl-4-Oxo-3,4-Dihydroquinazolin-6-Yl)amino]phenyl}propane-1-Sulfonamide;N-[2-cyano-3-[(3-methyl-4-oxoquinazolin-6-yl)amino]phenyl]propane-1-sulfonamide
N-(2-cyano-3-(3-methyl-4-oxo-3,4-dihydroquinazolin-6-ylamino)phenyl)propane-1-sulfonamide化学式
CAS
1396310-74-9
化学式
C19H19N5O3S
mdl
——
分子量
397.458
InChiKey
VBLJFIYCXZTIPN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    28
  • 可旋转键数:
    6
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.21
  • 拓扑面积:
    123
  • 氢给体数:
    2
  • 氢受体数:
    7

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] HETEROCYCLIC SULFONAMIDES AS RAF INHIBITORS<br/>[FR] SULFONAMIDES HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE RAF
    申请人:ARRAY BIOPHARMA INC
    公开号:WO2012118492A1
    公开(公告)日:2012-09-07
    Compounds of Formula (I) are useful for inhibition of Raf kinases. Methods of using compounds of Formula (I), stereoisomers, tautomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    化合物的化学式(I)对于抑制Raf激酶很有用。本文披露了使用化合物的方法(I),立体异构体,互变异构体及其药用可接受的盐,用于体外、体内和体内诊断、预防或治疗哺乳动物细胞中的这类疾病,或相关的病理状况。
  • Highly potent and selective 3-N-methylquinazoline-4(3H)-one based inhibitors of B-RafV600E kinase
    作者:Steve Wenglowsky、Li Ren、Jonas Grina、Joshua D. Hansen、Ellen R. Laird、David Moreno、Victoria Dinkel、Susan L. Gloor、Gregg Hastings、Sumeet Rana、Kevin Rasor、Hillary L. Sturgis、Walter C. Voegtli、Guy Vigers、Brandon Willis、Simon Mathieu、Joachim Rudolph
    DOI:10.1016/j.bmcl.2014.03.007
    日期:2014.4
    Herein we describe the design of a novel series of ATP competitive B-Raf inhibitors via structure-based methods. These 3-N-methylquinazoline-4(3H)-one based inhibitors exhibit both excellent cellular potency and striking B-Raf selectivity. Optimization led to the identification of compound 16, a potent, selective and orally available agent with excellent pharmacokinetic properties and robust tumor growth inhibition in xenograft studies. Our work also demonstrates that by replacing an aryl amide with an aryl sulfonamide, a multikinase inhibitor such as AZ-628, can be converted to a selective B-Raf inhibitor, a finding that should have broad application in kinase drug discovery. (C) 2014 Elsevier Ltd. All rights reserved.
查看更多